-
1
-
-
0034993741
-
Classes of c-KIT activating mutations: Proposed mechanisms of action and implications for disease classification and therapy
-
DOI 10.1016/S0145-2126(01)00028-5, PII S0145212601000285
-
Longley BJ, Reguera MJ, Ma Y: Classes of c-KIT activating mutations: Proposed mechanisms of action and implications for disease classification and therapy. Leuk Res 25:571-576, 2001 (Pubitemid 32506764)
-
(2001)
Leukemia Research
, vol.25
, Issue.7
, pp. 571-576
-
-
Longley, B.J.1
Reguera, M.J.2
Ma, Y.3
-
2
-
-
0041656424
-
Imatinib for systemic mast-cell disease
-
DOI 10.1016/S0140-6736(03)14115-3
-
Pardanani A, Elliott M, Reeder T, et al: Imatinib for systemic mast-cell disease. Lancet 362:535-537, 2003 (Pubitemid 36976719)
-
(2003)
Lancet
, vol.362
, Issue.9383
, pp. 535-537
-
-
Pardanani, A.1
Elliott, M.2
Reeder, T.3
Li, C.-Y.4
Baxter, E.J.5
Cross, N.C.P.6
Tefferi, A.7
-
3
-
-
0043169405
-
Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit
-
DOI 10.1016/S0301-472X(03)00112-7
-
Akin C, Brockow K, D'Ambrosio C, et al: Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 31:686-692, 2003 (Pubitemid 36945381)
-
(2003)
Experimental Hematology
, vol.31
, Issue.8
, pp. 686-692
-
-
Akin, C.1
Brockow, K.2
D'Ambrosio, C.3
Kirshenbaum, A.S.4
Ma, Y.5
Longley, B.J.6
Metcalfe, D.D.7
-
4
-
-
33745863150
-
Imatinib mesylate in the treatment of systemic mastocytosis: A phase II trial
-
DOI 10.1002/cncr.21996
-
Droogendijk HJ, Kluin-Nelemans HJ, Van Doormaal JJ, et al: Imatinib mesylate in the treatment of systemic mastocytosis: A phase II trial. Cancer 107:345-351, 2006 (Pubitemid 44036564)
-
(2006)
Cancer
, vol.107
, Issue.2
, pp. 345-351
-
-
Droogendijk, H.J.1
Kluin-Nelemans, H.J.C.2
Van Doormaal, J.J.3
Oranje, A.P.4
Van De, L.A.A.5
Van Daele, P.L.A.6
-
5
-
-
64249092051
-
Advanced mast cell disease: An Italian Hematological Multicenter experience
-
Pagano L, Valentini CG, Caira M, et al: Advanced mast cell disease: An Italian Hematological Multicenter experience. Int J Hematol 88:483-488, 2008
-
(2008)
Int J Hematol
, vol.88
, pp. 483-488
-
-
Pagano, L.1
Valentini, C.G.2
Caira, M.3
-
6
-
-
68649118339
-
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis
-
Vega-Ruiz A, Cortes JE, Sever M, et al: Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 33:1481-1484, 2009
-
(2009)
Leuk Res
, vol.33
, pp. 1481-1484
-
-
Vega-Ruiz, A.1
Cortes, J.E.2
Sever, M.3
-
7
-
-
79960629726
-
Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis
-
Wasag B, Niedoszytko M, Piskorz A, et al: Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis. Exp Hematol 39:859-865, 2011
-
(2011)
Exp Hematol
, vol.39
, pp. 859-865
-
-
Wasag, B.1
Niedoszytko, M.2
Piskorz, A.3
-
8
-
-
33947520803
-
Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation
-
DOI 10.1038/labinvest.3700524, PII 3700524
-
Nakagomi N, Hirota S: Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation. Lab Invest 87:365-371, 2007 (Pubitemid 46474567)
-
(2007)
Laboratory Investigation
, vol.87
, Issue.4
, pp. 365-371
-
-
Nakagomi, N.1
Hirota, S.2
-
9
-
-
10744228486
-
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy
-
DOI 10.1182/blood-2003-05-1627
-
Pardanani A, Ketterling RP, Brockman SR, et al: CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 102:3093-3096, 2003 (Pubitemid 37314742)
-
(2003)
Blood
, vol.102
, Issue.9
, pp. 3093-3096
-
-
Pardanani, A.1
Ketterling, R.P.2
Brockman, S.R.3
Flynn, H.C.4
Paternoster, S.F.5
Shearer, B.M.6
Reeder, T.L.7
Li, C.-Y.8
Cross, N.C.P.9
Cools, J.10
Gilliland, D.G.11
Dewald, G.W.12
Tefferi, A.13
-
10
-
-
1842579440
-
A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib
-
DOI 10.1182/blood-2003-11-3816
-
Akin C, Fumo G, Yavuz AS, et al: A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 103:3222-3225, 2004 (Pubitemid 38451702)
-
(2004)
Blood
, vol.103
, Issue.8
, pp. 3222-3225
-
-
Akin, C.1
Fumo, G.2
Yavuz, A.S.3
Lipsky, P.E.4
Neckers, L.5
Metcalfe, D.D.6
-
11
-
-
32844455834
-
A novel K509I mutation of KIT identified in familial mastocytosis - In vitro and in vivo responsiveness to imatinib therapy
-
DOI 10.1016/j.leukres.2005.08.015, PII S0145212605003218
-
Zhang LY, Smith ML, Schultheis B, et al: A novel K5091 mutation of KIT identified in familial mastocytosis - in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 30:373-378, 2006 (Pubitemid 43254957)
-
(2006)
Leukemia Research
, vol.30
, Issue.4
, pp. 373-378
-
-
Zhang, L.Y.1
Smith, M.L.2
Schultheis, B.3
Fitzgibbon, J.4
Lister, T.A.5
Melo, J.V.6
Cross, N.C.P.7
Cavenagh, J.D.8
-
12
-
-
52649177664
-
Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation
-
Hoffmann KM, Moser A, Lohse P, et al: Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation. Blood 112:1655-1657, 2008
-
(2008)
Blood
, vol.112
, pp. 1655-1657
-
-
Hoffmann, K.M.1
Moser, A.2
Lohse, P.3
-
13
-
-
33747336609
-
Well-differentiated systemic mastocytosis: A new disease variant with mature mast cell phenotype and lack of codon 816 c-kit mutations
-
Akin C, Escribano L, Núñez R, et al: Well-differentiated systemic mastocytosis: A new disease variant with mature mast cell phenotype and lack of codon 816 c-kit mutations. J Allergy Clin Immunol 113:S327, 2004
-
(2004)
J Allergy Clin Immunol
, vol.113
-
-
Akin, C.1
Escribano, L.2
Núñez, R.3
-
14
-
-
77949268924
-
Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes
-
Teodosio C, García-Montero AC, Jara-Acevedo M, et al: Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J Allergy Clin Immunol 125:719-726, 2010
-
(2010)
J Allergy Clin Immunol
, vol.125
, pp. 719-726
-
-
Teodosio, C.1
García-Montero, A.C.2
Jara-Acevedo, M.3
-
15
-
-
80052422183
-
Evaluation of the WHO criteria for the classification of patients with mastocytosis
-
Sánchez-Munoz L, Alvarez-Twose I, García-Montero AC, et al: Evaluation of the WHO criteria for the classification of patients with mastocytosis. Mod Pathol 24:1157-1168, 2011
-
(2011)
Mod Pathol
, vol.24
, pp. 1157-1168
-
-
Sánchez-Munoz, L.1
Alvarez-Twose, I.2
García-Montero, A.C.3
-
16
-
-
33749368009
-
KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients
-
DOI 10.1182/blood-2006-04-015545
-
García-Montero AC, Jara-Acevedo M, Teodosio C, et al: KIT mutation in mast cells and other bone marrow haematopoietic cell lineages in systemic mast cell disorders. A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 108:2366-2372, 2006 (Pubitemid 44497521)
-
(2006)
Blood
, vol.108
, Issue.7
, pp. 2366-2372
-
-
Garcia-Montero, A.C.1
Jara-Acevedo, M.2
Teodosio, C.3
Sanchez, M.L.4
Nunez, R.5
Prados, A.6
Aldanondo, I.7
Sanchez, L.8
Dominguez, M.9
Botana, L.M.10
Sanchez-Jimenez, F.11
Sotlar, K.12
Almeida, J.13
Escribano, L.14
Orfao, A.15
-
17
-
-
0035810142
-
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
-
DOI 10.1056/NEJM200104053441402
-
Druker BJ, Sawyers CL, Kantarjian H, et al: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042, 2001 (Pubitemid 32267973)
-
(2001)
New England Journal of Medicine
, vol.344
, Issue.14
, pp. 1038-1042
-
-
Druker, B.J.1
Sawyers, C.L.2
Kantarjian, H.3
Resta, D.J.4
Reese, S.F.5
Ford, J.M.6
Capdeville, R.7
Talpaz, M.8
-
18
-
-
0035810147
-
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
-
DOI 10.1056/NEJM200104053441401
-
Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001 (Pubitemid 32267972)
-
(2001)
New England Journal of Medicine
, vol.344
, Issue.14
, pp. 1031-1037
-
-
Druker, B.J.1
Talpaz, M.2
Resta, D.J.3
Peng, B.4
Buchdunger, E.5
Ford, J.M.6
Lydon, N.B.7
Kantarjian, H.8
Capdeville, R.9
Ohno-Jones, S.10
Sawyers, C.L.11
-
19
-
-
0035823530
-
Case report: Rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate
-
Schaller JL, Burkland GA: Case report: Rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed 3:9, 2001
-
(2001)
MedGenMed
, vol.3
, pp. 9
-
-
Schaller, J.L.1
Burkland, G.A.2
-
20
-
-
0036063077
-
Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate
-
DOI 10.1016/S0145-2126(02)00046-2, PII S0145212602000462
-
Ault P, Cortes J, Koller C, et al: Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res 26:881-884, 2002 (Pubitemid 34790218)
-
(2002)
Leukemia Research
, vol.26
, Issue.9
, pp. 881-884
-
-
Ault, P.1
Cortes, J.2
Koller, C.3
Kaled, E.S.4
Kantarjian, H.5
-
21
-
-
10744228476
-
Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome
-
Cortes J, Ault P, Koller C, et al: Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 101:4714-4716, 2003 (Pubitemid 36857726)
-
(2003)
Blood
, vol.101
, Issue.12
, pp. 4714-4716
-
-
Cortes, J.1
Ault, P.2
Koller, C.3
Thomas, D.4
Ferrajoli, A.5
Wierda, W.6
Rios, M.B.7
Letvak, L.8
Kaled, E.S.9
Kantarjian, H.10
-
22
-
-
0038792233
-
Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness
-
Klion AD, Noel P, Akin C, et al: Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 101:4660-4666, 2003 (Pubitemid 36857718)
-
(2003)
Blood
, vol.101
, Issue.12
, pp. 4660-4666
-
-
Klion, A.D.1
Noel, P.2
Akin, C.3
Law, M.A.4
Gilliland, D.G.5
Cools, J.6
Metcalfe, D.D.7
Nutman, T.B.8
-
23
-
-
0038386031
-
Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders
-
DOI 10.1182/blood-2002-10-3103
-
Pardanani A, Reeder T, Porrata LF, et al: Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 101:3391-3397, 2003 (Pubitemid 36857919)
-
(2003)
Blood
, vol.101
, Issue.9
, pp. 3391-3397
-
-
Pardanani, A.1
Reeder, T.2
Porrata, L.F.3
Li, C.-Y.4
Tazelaar, H.D.5
Baxter, E.J.6
Witzig, T.E.7
Cross, N.C.P.8
Tefferi, A.9
-
24
-
-
0035810148
-
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
-
DOI 10.1056/NEJM200104053441404
-
Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052-1056, 2001 (Pubitemid 32267975)
-
(2001)
New England Journal of Medicine
, vol.344
, Issue.14
, pp. 1052-1056
-
-
Joensuu, H.1
Roberts, P.J.2
Sarlomo-Rikala, M.3
Andersson, L.C.4
Tervahartiala, P.5
Tuveson, D.6
Silberman, S.L.7
Capdeville, R.8
Dimitrijevic, S.9
Druker, B.10
Demetri, G.D.11
-
25
-
-
0037103424
-
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
-
DOI 10.1056/NEJMoa020461
-
Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002 (Pubitemid 34879334)
-
(2002)
New England Journal of Medicine
, vol.347
, Issue.7
, pp. 472-480
-
-
Demetri, G.D.1
Von Mehren, M.2
Blanke, C.D.3
Van Den, A.A.D.4
Eisenberg, B.5
Roberts, P.J.6
Heinrich, M.C.7
Tuveson, D.A.8
Singer, S.9
Janicek, M.10
Fletcher, J.A.11
Silverman, S.G.12
Silberman, S.L.13
Capdeville, R.14
Kiese, B.15
Peng, B.16
Dimitrijevic, S.17
Druker, B.J.18
Corless, C.19
Fletcher, C.D.M.20
Joensuu, H.21
more..
-
26
-
-
0036493872
-
The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wildtype kinases and those with regulatory-type mutations
-
Ma Y, Zeng S, Metcalfe DD, et al: The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wildtype kinases and those with regulatory-type mutations. Blood 99:1741-1744, 2002
-
(2002)
Blood
, vol.99
, pp. 1741-1744
-
-
Ma, Y.1
Zeng, S.2
Metcalfe, D.D.3
-
27
-
-
2942542387
-
Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase
-
Mol CD, Dougan DR, Schneider TR, et al: Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 279:31655-31663, 2004
-
(2004)
J Biol Chem
, vol.279
, pp. 31655-31663
-
-
Mol, C.D.1
Dougan, D.R.2
Schneider, T.R.3
-
28
-
-
0038731316
-
Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant
-
Frost MJ, Ferrao PT, Hughes TP, et al: Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 1:1115-1124, 2002
-
(2002)
Mol Cancer Ther
, vol.1
, pp. 1115-1124
-
-
Frost, M.J.1
Ferrao, P.T.2
Hughes, T.P.3
-
29
-
-
24144503371
-
Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis
-
DOI 10.1053/j.gastro.2005.06.060, PII S0016508505013466
-
Hartmann K, Wardelmann E, Ma Y, et al: Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology 129:1042-1046, 2005 (Pubitemid 41242694)
-
(2005)
Gastroenterology
, vol.129
, Issue.3
, pp. 1042-1046
-
-
Hartmann, K.1
Wardelmann, E.2
Ma, Y.3
Merkelbach-Bruse, S.4
Preussner, L.M.5
Woolery, C.6
Baldus, S.E.7
Heinicke, T.8
Thiele, J.9
Buettner, R.10
Longley, B.J.11
-
30
-
-
79955998389
-
A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib
-
Mital A, Piskorz A, Lewandowski K, et al: A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib. Eur J Haematol 86:531-535, 2011
-
(2011)
Eur J Haematol
, vol.86
, pp. 531-535
-
-
Mital, A.1
Piskorz, A.2
Lewandowski, K.3
-
31
-
-
77951066096
-
A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisions
-
Pardanani A, Tefferi A: A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisions. Eur J Haematol 84:371-378, 2010
-
(2010)
Eur J Haematol
, vol.84
, pp. 371-378
-
-
Pardanani, A.1
Tefferi, A.2
-
32
-
-
79958788970
-
Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis
-
Jung AG, Horny HP, Sotlar K, et al: Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis. J Am Acad Dermatol 65:224-226, 2011
-
(2011)
J Am Acad Dermatol
, vol.65
, pp. 224-226
-
-
Jung, A.G.1
Horny, H.P.2
Sotlar, K.3
-
33
-
-
69349102308
-
Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients
-
Escribano L, Alvarez-Twose I, Sánchez-Munoz L, et al: Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 124:514-521, 2009
-
(2009)
J Allergy Clin Immunol
, vol.124
, pp. 514-521
-
-
Escribano, L.1
Alvarez-Twose, I.2
Sánchez-Munoz, L.3
-
34
-
-
76749089140
-
Systemic mastocytosis in adults: A review on prognosis and treatment based on 342 Mayo Clinic patients and current literature
-
Pardanani A, Tefferi A: Systemic mastocytosis in adults: A review on prognosis and treatment based on 342 Mayo Clinic patients and current literature. Curr Opin Hematol 17:125-132, 2010
-
(2010)
Curr Opin Hematol
, vol.17
, pp. 125-132
-
-
Pardanani, A.1
Tefferi, A.2
-
35
-
-
0018411931
-
Production and life span of cutaneous mast cells in young rats
-
Kiernan JA: Production and life span of cutaneous mast cells in young rats. J Anat 128:225-238, 1979
-
(1979)
J Anat
, vol.128
, pp. 225-238
-
-
Kiernan, J.A.1
|